ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
Background and purpose Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods Radiotherapy (50.4 Gy/28...
Những tác giả chính: | Wilson, J, Fokas, E, Dutton, S, Hawkins, M, al., E |
---|---|
Định dạng: | Journal article |
Được phát hành: |
Elsevier
2016
|
Những quyển sách tương tự
-
ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
Bằng: Wilson, J, et al.
Được phát hành: (2017) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
Bằng: Brunner, T, et al.
Được phát hành: (2008) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
Bằng: Brunner, T, et al.
Được phát hành: (2008) -
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
Bằng: Brunner, T, et al.
Được phát hành: (2008) -
HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
Bằng: Unaí Tupinambás, et al.